Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ChemoCentryx, Inc. CCXI
$51.99
На 18:00, 12 мая 2023
+18.62%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
52.00
-
week52low
14.95
-
Revenue
32224000
-
P/E TTM
-35
-
Beta
1.22955000
-
EPS
-2.00500000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 ноя 2022 г. в 01:15
Описание компании
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Stifel | Hold | Buy | 10 авг 2022 г. |
| SVB Leerink | Market Perform | Outperform | 05 авг 2022 г. |
| Raymond James | Market Perform | Strong Buy | 05 авг 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 05 авг 2022 г. |
| Canaccord Genuity | Hold | Buy | 05 авг 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Jain Rita | D | 0 | 11600 | 20 окт 2022 г. |
| Jain Rita | D | 0 | 11600 | 20 окт 2022 г. |
| Jain Rita | D | 0 | 11600 | 20 окт 2022 г. |
| Edwards Thomas A. | D | 0 | 15723 | 20 окт 2022 г. |
| Edwards Thomas A. | D | 0 | 15723 | 20 окт 2022 г. |
| Edwards Thomas A. | D | 0 | 15723 | 20 окт 2022 г. |
| Herron Jennifer Lyn | D | 0 | 17237 | 20 окт 2022 г. |
| KANAYA SUSAN M | D | 0 | 90968 | 20 окт 2022 г. |
| KANAYA SUSAN M | D | 0 | 90968 | 20 окт 2022 г. |
| KANAYA SUSAN M | D | 0 | 90968 | 20 окт 2022 г. |
Новостная лента
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
06 окт 2022 г. в 11:17
Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
Cancer-Drug Maker's Solid Position And Successful Drug Record Drive Growth
Investors Business Daily
08 сент 2022 г. в 17:09
Cancer-drug maker Amgen solidified its position in a highly competitive market by acquiring its rival Mirati Therapeutics.
Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?
Zacks Investment Research
07 сент 2022 г. в 12:48
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?
Here's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy
Zacks Investment Research
16 авг 2022 г. в 13:33
Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Get ready for more merger mania in pharma sector the rest of the year
Market Watch
09 авг 2022 г. в 14:43
Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.